The Medicines Manufacturing Innovation Centre is a collaboration between CPI, University of Strathclyde, UK Research & Innovation, Scottish Enterprise and founding industry partners, AstraZeneca and GSK. The centre will ensure the UK is a technology and innovation leader in pharmaceutical manufacturing. The initial focus will be on technology translation for small molecule drug manufacture.
With a collaborative innovation culture and state-of the art facilities, the new facility will enable industry, academia, healthcare providers and regulators to work collaboratively to address challenges and maximise technology opportunities within the medicines supply chain.
The MMIC will carry out industrial scale pilot production of drugs using continuous manufacturing techniques developed in the University’s Continuous Manufacturing and Crystallisation Centre (CMAC) – helping to make precision medicine possible and economically-viable. The MMIC has been awarded £42M capital funding from the Scottish and UK Governments and from major industry partners, including AstraZeneca and GSK, under the UK Government Industrial Strategy.
The Centre is currently under construction and is due for completion late 2021 and will be operational in early 2022. It is expected to eventually house over 80 staff in both technical and non-technical roles.
Ageing populations, the cost of drug development, and resource constraints impeding the adoption of emergent technologies are just some of the challenges facing the pharmaceutical industry today. The increasing financial burden on the healthcare system as a whole has led to a pressing need for more cost-effective medication, which in turn makes the potential of digital and data-enabled healthcare even more important.
The aim of the centre is to accelerate the development of a new generation of manufacturing processes and to help companies integrate these within their existing models. The evolution of pharmaceutical clinical development and manufacture is vital and there are many ways the centre can bring about change.
Novel techniques for producing patient-centric medicines, real-time release of drugs and integrated process analytics are all able to drive the transformation of medicines manufacturing and reduce the financial burden on payers and governments. Flexible and modular manufacturing for stratified medicine production, the ability to use next-generation technology in a GMP-capable environment and enabling efficient production can also protect future generations by bringing new medicines to market safely and quickly.
If you would like to reach out to discuss anything from the above case study, please get in touch.
Let us know if you would like to discuss contributing to the case studies we currently profile.